CA2531836A1 - Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions. - Google Patents
Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions. Download PDFInfo
- Publication number
- CA2531836A1 CA2531836A1 CA002531836A CA2531836A CA2531836A1 CA 2531836 A1 CA2531836 A1 CA 2531836A1 CA 002531836 A CA002531836 A CA 002531836A CA 2531836 A CA2531836 A CA 2531836A CA 2531836 A1 CA2531836 A1 CA 2531836A1
- Authority
- CA
- Canada
- Prior art keywords
- preventing
- treating
- alleviating
- cholesterol
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61545603A | 2003-07-09 | 2003-07-09 | |
US10/615,456 | 2003-07-09 | ||
PCT/CA2004/000999 WO2005005453A2 (en) | 2003-07-09 | 2004-07-09 | Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions. |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2531836A1 true CA2531836A1 (en) | 2005-01-20 |
Family
ID=34062381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002531836A Abandoned CA2531836A1 (en) | 2003-07-09 | 2004-07-09 | Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1644399A2 (ko) |
JP (1) | JP2007525470A (ko) |
KR (1) | KR20060052792A (ko) |
CN (1) | CN1832957A (ko) |
AU (1) | AU2004255285A1 (ko) |
BR (1) | BRPI0412439A (ko) |
CA (1) | CA2531836A1 (ko) |
MX (1) | MXPA06000326A (ko) |
NO (1) | NO20060632L (ko) |
NZ (1) | NZ545087A (ko) |
PL (1) | PL379516A1 (ko) |
RU (1) | RU2006103797A (ko) |
WO (1) | WO2005005453A2 (ko) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
WO2008032980A1 (en) * | 2006-09-12 | 2008-03-20 | Cns Pharm Korea Co., Ltd. | Novel stigmasterol derivative or pharmaceutically acceptable salt thereof, method of producing the same, and composition containing the same to inhibit obesity or to prevent and treat hyperlipidemia |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP6262723B2 (ja) * | 2012-05-07 | 2018-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | オキシステロールアナログoxy133は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する |
KR20140081339A (ko) * | 2012-12-21 | 2014-07-01 | 부경대학교 산학협력단 | 푸코스테롤을 유효성분으로 포함하는 퇴행성 신경질환 예방 또는 치료용 약제학적 조성물 |
CA2911205A1 (en) | 2013-05-02 | 2014-11-06 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
EP3617217B1 (en) | 2014-12-09 | 2022-09-07 | Warsaw Orthopedic, Inc. | Process for the production of oxysterols |
CN104434927A (zh) * | 2014-12-16 | 2015-03-25 | 吉林农业大学 | 丙二酸双环戊烷并多氢菲酯b在制备降血压药物中的应用 |
US9987289B2 (en) | 2015-07-10 | 2018-06-05 | Warsaw Orthopedic, Inc. | Slow release oxysterols and methods of use |
US10632230B2 (en) | 2015-07-10 | 2020-04-28 | Warsaw Orthopedic, Inc. | Implants having a high drug load of an oxysterol and methods of use |
US9877836B2 (en) | 2015-07-10 | 2018-01-30 | Warsaw Orthopedic, Inc. | Compression resistant implants including an oxysterol and methods of use |
CN105055404B (zh) * | 2015-08-19 | 2017-07-18 | 四川大学 | Hmgcs2抑制剂在制备治疗***成瘾的药物中的用途 |
CN105087609B (zh) * | 2015-08-19 | 2018-10-23 | 四川大学 | 一种重组慢病毒及其在制备治疗***成瘾的药物中的用途 |
US10688222B2 (en) | 2016-11-21 | 2020-06-23 | Warsaw Orthopedic, Inc. | Lyophilized moldable implants containing an oxysterol |
US11384114B2 (en) | 2016-12-09 | 2022-07-12 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
US10434106B2 (en) * | 2017-05-19 | 2019-10-08 | Warsaw Orthopedic, Inc. | Oxysterol-statin compounds for bone growth |
US11464888B2 (en) | 2017-06-12 | 2022-10-11 | Warsaw Orthopedic, Inc. | Moldable formulations containing an oxysterol in an acellular tissue matrix |
KR102139994B1 (ko) * | 2017-10-25 | 2020-07-31 | 대구대학교 산학협력단 | 스티그마스테롤을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물 |
CN113143935B (zh) * | 2021-02-01 | 2022-10-11 | 广东药科大学 | 豆甾醇在制备改善心肌肥厚的药物中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5216015A (en) * | 1991-02-05 | 1993-06-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having hypocholesterolemic properties |
RU2002101483A (ru) * | 1999-06-23 | 2003-09-20 | Форбз Меди-Тек Инк. (Ca) | Коньюгаты фитостерола или фитостанола с аскорбиновой кислотой и их применение для лечения или профилактики сердечно-сосудистых заболеваний |
-
2004
- 2004-07-09 AU AU2004255285A patent/AU2004255285A1/en not_active Abandoned
- 2004-07-09 EP EP04737936A patent/EP1644399A2/en not_active Withdrawn
- 2004-07-09 PL PL379516A patent/PL379516A1/pl unknown
- 2004-07-09 CN CNA2004800228667A patent/CN1832957A/zh active Pending
- 2004-07-09 BR BRPI0412439-1A patent/BRPI0412439A/pt not_active IP Right Cessation
- 2004-07-09 CA CA002531836A patent/CA2531836A1/en not_active Abandoned
- 2004-07-09 JP JP2006517922A patent/JP2007525470A/ja not_active Withdrawn
- 2004-07-09 RU RU2006103797/04A patent/RU2006103797A/ru not_active Application Discontinuation
- 2004-07-09 NZ NZ545087A patent/NZ545087A/en unknown
- 2004-07-09 MX MXPA06000326A patent/MXPA06000326A/es unknown
- 2004-07-09 KR KR1020067000470A patent/KR20060052792A/ko not_active Application Discontinuation
- 2004-07-09 WO PCT/CA2004/000999 patent/WO2005005453A2/en active Search and Examination
-
2006
- 2006-02-09 NO NO20060632A patent/NO20060632L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0412439A (pt) | 2006-09-05 |
MXPA06000326A (es) | 2006-03-30 |
KR20060052792A (ko) | 2006-05-19 |
WO2005005453A2 (en) | 2005-01-20 |
EP1644399A2 (en) | 2006-04-12 |
JP2007525470A (ja) | 2007-09-06 |
AU2004255285A1 (en) | 2005-01-20 |
NO20060632L (no) | 2006-04-06 |
WO2005005453A3 (en) | 2005-06-09 |
CN1832957A (zh) | 2006-09-13 |
RU2006103797A (ru) | 2006-07-27 |
PL379516A1 (pl) | 2006-10-02 |
NZ545087A (en) | 2009-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2531836A1 (en) | Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions. | |
US7645748B2 (en) | Sterol/stanol phosphorylnitroderivatives and use thereof | |
EP1353696B1 (en) | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
JP2005533810A (ja) | 新規な抗コレステロール組成物及びその使用方法 | |
EP3383377B1 (en) | Compounds and methods for inhibiting production of trimethylamine | |
US5929062A (en) | Oxysterol inhibition of dietary cholesterol uptake | |
WO2005102357A1 (en) | Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof | |
JP4839221B2 (ja) | Hdlを高める併用療法用複合物 | |
US8895079B2 (en) | Combinations of botanical extracts for promoting cardiovascular health | |
US20040014806A1 (en) | Methods and compositions for lowering levels of blood lipids | |
WO2007112572A1 (en) | Sterols/stanols chemically linked to nitrogen releasing compounds and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders | |
WO2005042692A2 (en) | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors | |
JP2023143940A (ja) | 新規な組成物、組み合わせ及びその方法を用いた標的薬物救済 | |
US6297218B1 (en) | Phospholipid complexes prepared from extracts of Vitis vinifera as anti-atherosclerotic agents | |
WO2001066560A2 (en) | Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders | |
JP5091859B2 (ja) | アシル−CoA:コレステロールアシルトランスフェラーゼ阻害用組成物 | |
KR20050084572A (ko) | 스테롤 및/또는 스탄올 및 특정한 종류의 항염증제를포함하는 유도체, 및 심혈관 질환을 치료 또는 예방하는이들의 용도 | |
US20030232797A1 (en) | Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders | |
US20040236125A1 (en) | Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation | |
EA009918B1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ВЫСШИЕ ПЕРВИЧНЫЕ АЛИФАТИЧЕСКИЕ СПИРТЫ И ИНГИБИТОР ГМГ-КоА-РЕДУКТАЗЫ, И СПОСОБ ИХ ПОЛУЧЕНИЯ | |
Heidker | Metabolic Effects of a Grape Seed Procyanidin Extract on Risk Factors of Cardiovascular Disease | |
Thompson | New developments in pharmacotherapy | |
CN101120942A (zh) | 治疗心脑血管疾病的复方药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |